Why Making Dramatic Moves: Chiasma, Inc. (NASDAQ:CHMA), Eagle Pharmaceuticals Inc. (NASDAQ:EGRX), The Coca-Cola Company (NYSE:KO), Bristol-Myers Squibb Company (NYSE:BMY),

Chiasma, Inc. (NASDAQ:CHMA) announced its support for Rare Disease Day 2016. In honor of Rare Disease Day, President and Chief Executive Officer Mark Leuchtenberger will join local patients, caregivers, policymakers and supporters at the Massachusetts State House today to raise awareness about under-recognized, under-treated and life-threatening illnesses.

Chiasma, Inc. (NASDAQ:CHMA) belongs to Healthcare sector. Its weekly performance is -10.60%. On last trading day company shares ended up at $9.87. Chiasma, Inc. (NASDAQ:CHMA) distance from 50-day simple moving average (SMA50) is -1.71%.

On 25 February, Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) announced its financial results for the three- and twelve-month periods ended December 31, 2015 Product sales increased to $2.9 million compared to $1.5 million for the three months ended December 31, 2014;

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) shares moved down -7.07% in last trading session and ended the day at $63.39. EGRX Gross Margin is 67.40% and its return on assets is -4.00%. Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) quarterly performance is -27.63%.

On 25 February, The Coca-Cola Company (NYSE:KO) is toasting the Denver Broncos Super Bowl win with a collectible can. The collectible championship cans will only be available in Colorado, and while supplies last

The Coca-Cola Company (NYSE:KO) belongs to Consumer Goods sector. Its net profit margin is 16.60% and weekly performance is -1.84%. On last trading day company shares ended up at $43.13. The Coca-Cola Company (NYSE:KO) distance from 50-day simple moving average (SMA50) is 0.86%.

On 26 February, Bristol-Myers Squibb Company (NYSE:BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Opdivo (nivolumab) for two new indications – adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy, and adults with advanced renal cell carcinoma (RCC) after prior therapy. Both indications are supported by Phase 3 studies in which Opdivodemonstrated a survival benefit versus a standard of care.

Bristol-Myers Squibb Company (NYSE:BMY) shares fell -0.51% in last trading session and ended the day at $61.93. BMY Gross Margin is 76.90% and its return on assets is 4.90%. Bristol-Myers Squibb Company (NYSE:BMY) quarterly performance is -8.54%.

Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and year end results for 2015 will be released on Tuesday, March 8, 2016, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

Cerus Corporation (NASDAQ:CERS) shares moved down -3.54% in last trading session and ended the day at $4.90. CERS Gross Margin is 30.10% and its return on assets is -48.00%. Cerus Corporation (NASDAQ:CERS) quarterly performance is -13.12%.

Leave a Reply

Your email address will not be published. Required fields are marked *